CL2021003196A1 - Combination therapies targeting pd-1, tim-3, and lag-3 (divisional application no. 201902850) - Google Patents

Combination therapies targeting pd-1, tim-3, and lag-3 (divisional application no. 201902850)

Info

Publication number
CL2021003196A1
CL2021003196A1 CL2021003196A CL2021003196A CL2021003196A1 CL 2021003196 A1 CL2021003196 A1 CL 2021003196A1 CL 2021003196 A CL2021003196 A CL 2021003196A CL 2021003196 A CL2021003196 A CL 2021003196A CL 2021003196 A1 CL2021003196 A1 CL 2021003196A1
Authority
CL
Chile
Prior art keywords
tim
lag
combination therapies
divisional application
therapies targeting
Prior art date
Application number
CL2021003196A
Other languages
Spanish (es)
Inventor
Trine Lindsted
Monika Gad
Michael Monrad Grandal
Michael Kragh
Mikkel Wandahl Pedersen
Camilla Fröhlich
Eva Maria Carlsen Melander
Johan Lantto
Ivan David Horak
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of CL2021003196A1 publication Critical patent/CL2021003196A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Esta invención se refiere a terapias combinadas dirigidas a dos o todos de PD-1, TIM-3 y LAG-3 mediante el uso de anticuerpos específicos para estos objetivos en pacientes que necesitan una inmunidad potenciada. Además, se incluyen en la invención composiciones útiles en las terapias. Las terapias son útiles en el tratamiento de enfermedades tales como el cáncer.This invention relates to combination therapies targeting two or all of PD-1, TIM-3 and LAG-3 through the use of antibodies specific for these targets in patients in need of enhanced immunity. In addition, compositions useful in therapies are included in the invention. The therapies are useful in treating diseases such as cancer.

CL2021003196A 2017-04-05 2021-12-01 Combination therapies targeting pd-1, tim-3, and lag-3 (divisional application no. 201902850) CL2021003196A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762481973P 2017-04-05 2017-04-05

Publications (1)

Publication Number Publication Date
CL2021003196A1 true CL2021003196A1 (en) 2022-09-23

Family

ID=62027945

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019002850A CL2019002850A1 (en) 2017-04-05 2019-10-04 Combination therapies targeting pd-1, tim-3, and lag-3.
CL2021003196A CL2021003196A1 (en) 2017-04-05 2021-12-01 Combination therapies targeting pd-1, tim-3, and lag-3 (divisional application no. 201902850)

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2019002850A CL2019002850A1 (en) 2017-04-05 2019-10-04 Combination therapies targeting pd-1, tim-3, and lag-3.

Country Status (19)

Country Link
US (2) US11939380B2 (en)
EP (3) EP4116328A1 (en)
JP (3) JP2020513009A (en)
KR (2) KR20190137105A (en)
CN (2) CN114984209A (en)
AU (2) AU2018247916A1 (en)
BR (1) BR112019020662A2 (en)
CA (2) CA3185303A1 (en)
CL (2) CL2019002850A1 (en)
CO (1) CO2019012080A2 (en)
EA (1) EA201992350A1 (en)
IL (1) IL269644A (en)
MA (1) MA49042A (en)
MX (2) MX2019011961A (en)
PE (1) PE20191741A1 (en)
PH (1) PH12019502191A1 (en)
SG (2) SG10201912941PA (en)
TW (2) TWI822101B (en)
WO (1) WO2018185232A1 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3443009T1 (en) 2016-04-12 2022-04-29 Symphogen A/S Anti-tim-3 antibodies and compositions
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
MA46529A (en) 2016-10-11 2019-08-21 Agenus Inc ANTI-LAG-3 ANTIBODIES AND PROCESSES FOR USE
WO2018069500A2 (en) 2016-10-13 2018-04-19 Symphogen A/S Anti-lag-3 antibodies and compositions
BR112019017329A2 (en) 2017-04-03 2020-04-14 Hoffmann La Roche immunoconjugates, one or more polynucleotides and vectors, methods for the production of an immunoconjugate, treatment of a disease and for the stimulation of the immune system, composition, use of the immunoconjugate, invention and uses of the composition
EA201992350A1 (en) * 2017-04-05 2020-03-23 Симфоген А/С COMBINED MEDICINES AIMED AT PD-1, TIM-3 AND LAG-3
CN116375876A (en) 2017-04-05 2023-07-04 豪夫迈·罗氏有限公司 Bispecific antibodies that specifically bind PD1 and LAG3
US10894833B2 (en) * 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
CN111253485A (en) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 Anti-human TIM-3 monoclonal antibody and application thereof
WO2020232019A1 (en) * 2019-05-13 2020-11-19 Regeneron Pharmaceuticals, Inc. Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
CN113214396B (en) * 2020-07-31 2022-04-19 北京市神经外科研究所 Single-chain antibody of anti-TIM 3 and application thereof in preparing medicine for treating tumor
CN112812179B (en) * 2021-01-19 2022-07-22 北京大学 High-affinity high-specificity anti-CMTM 6 monoclonal antibody and application thereof
WO2023240082A2 (en) * 2022-06-07 2023-12-14 Incyte Corporation Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer
WO2024041652A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment
WO2024041651A1 (en) * 2022-08-25 2024-02-29 Beigene, Ltd. Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies
WO2024051670A1 (en) * 2022-09-06 2024-03-14 正大天晴药业集团股份有限公司 Pharmaceutical combination of antibody binding to tim-3 and antibody binding to pd-1

Family Cites Families (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
EP0216846B2 (en) 1985-04-01 1995-04-26 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
CN1110557C (en) 1994-05-06 2003-06-04 古斯达威罗斯研究所 LAG-3 protein soluble polypeptide fractions, method of production, therapeutic composition and anti-idiotype antibody
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
ES2637801T3 (en) 2000-04-11 2017-10-17 Genentech, Inc. Multivalent antibodies and uses thereof
EP1762617A1 (en) 2003-01-07 2007-03-14 Symphogen A/S Method for manufacturing recombinant polyclonal proteins
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2008019817A1 (en) 2006-08-17 2008-02-21 F. Hoffmann-La Roche Ag A conjugate of an antibody against ccr5 and an antifusogenic peptide
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PL2152872T3 (en) 2007-05-25 2011-03-31 Symphogen As Method for manufacturing a recombinant polyclonal protein
SI2170959T1 (en) 2007-06-18 2014-04-30 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
EP2252319A2 (en) 2008-01-29 2010-11-24 The Brigham and Women's Hospital, Inc. Methods for modulating a population of myeloid-derived suppressor cells and uses thereof
CA2722348A1 (en) 2008-04-23 2009-10-29 Symphogen A/S Methods for manufacturing a polyclonal protein
AR072999A1 (en) 2008-08-11 2010-10-06 Medarex Inc HUMAN ANTIBODIES THAT JOIN GEN 3 OF LYMPHOCYTARY ACTIVATION (LAG-3) AND THE USES OF THESE
WO2010029434A1 (en) 2008-09-12 2010-03-18 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
AU2009290544B2 (en) 2008-09-12 2015-07-16 Oxford University Innovation Limited PD-1 specific antibodies and uses thereof
US20110224094A1 (en) 2008-10-06 2011-09-15 Symphogen A/S Method for identifying and selecting drug candidates for combinatorial drug products
JP5569946B2 (en) 2009-01-26 2014-08-13 国立大学法人 岡山大学 Immunosuppressants and preventive and therapeutic agents for autoimmune diseases
WO2010117057A1 (en) 2009-04-10 2010-10-14 協和発酵キリン株式会社 Method for treatment of blood tumor using anti-tim-3 antibody
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
AU2011262758B8 (en) 2010-06-11 2014-09-04 Kyowa Kirin Co., Ltd. Anti-tim-3 antibody
CA2802344C (en) * 2010-06-18 2023-06-13 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
KR101773120B1 (en) 2010-11-01 2017-08-30 심포젠 에이/에스 Anti-her3 antibodies and compositions
KR102289394B1 (en) 2011-03-31 2021-08-13 머크 샤프 앤드 돔 코포레이션 Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
CN104428318B (en) 2012-05-02 2018-09-25 西福根有限公司 The general HER antibody compositions of humanization
AR091649A1 (en) 2012-07-02 2015-02-18 Bristol Myers Squibb Co OPTIMIZATION OF ANTIBODIES THAT FIX THE LYMPHOCYTE ACTIVATION GEN 3 (LAG-3) AND ITS USES
KR20150136061A (en) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 Administration of an anti-activin-a compound to a subject
ME03796B (en) 2013-03-15 2021-04-20 Glaxosmithkline Ip Dev Ltd Anti-lag-3 binding proteins
CN104250302B (en) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 The anti-antibody of PD 1 and its application
CN112552401B (en) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 anti-PD 1 antibodies and their use as therapeutic and diagnostic agents
SG11201601763SA (en) * 2013-09-20 2016-04-28 Bristol Myers Squibb Co Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
DK3081576T3 (en) 2013-12-12 2019-10-21 Shanghai hengrui pharmaceutical co ltd PD-1 ANTIBODY, ANTI-BINDING FRAGMENT THEREOF AND MEDICAL USE THEREOF
WO2015175340A1 (en) * 2014-05-13 2015-11-19 Bavarian Nordic, Inc. Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against tim-3
TWI681969B (en) 2014-01-23 2020-01-11 美商再生元醫藥公司 Human antibodies to pd-1
JOP20200094A1 (en) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc Antibody molecules to pd-1 and uses thereof
CN103936853B (en) 2014-01-26 2016-08-17 中国人民解放军军事医学科学院基础医学研究所 A kind of detection TIM-3 test kit and using method thereof
JOP20200096A1 (en) 2014-01-31 2017-06-16 Children’S Medical Center Corp Antibody molecules to tim-3 and uses thereof
KR20230097209A (en) 2014-03-12 2023-06-30 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
KR102442436B1 (en) 2014-03-14 2022-09-15 노파르티스 아게 Antibody molecules to lag-3 and uses thereof
AU2015292678B2 (en) 2014-07-22 2020-10-22 Cb Therapeutics, Inc. Anti-PD-1 antibodies
JO3663B1 (en) 2014-08-19 2020-08-27 Merck Sharp & Dohme Anti-lag3 antibodies and antigen-binding fragments
TWI595006B (en) 2014-12-09 2017-08-11 禮納特神經系統科學公司 Anti-pd-1 antibodies and methods of use thereof
ES2881484T3 (en) 2014-12-22 2021-11-29 Pd 1 Acquisition Group Llc Anti-PD-1 antibodies
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
MA41463A (en) * 2015-02-03 2017-12-12 Anaptysbio Inc ANTIBODIES DIRECTED AGAINST LYMPHOCYTE ACTIVATION GEN 3 (LAG-3)
WO2016144803A2 (en) 2015-03-06 2016-09-15 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP3337826A1 (en) 2015-08-20 2018-06-27 Sutro Biopharma, Inc. Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies
US20210284734A1 (en) 2015-10-02 2021-09-16 Symphogen A/S Anti-pd-1 antibodies and compositions
SI3356411T1 (en) 2015-10-02 2021-09-30 F. Hoffmann-La Roche Ag Bispecific antibodies specific for pd1 and tim3
SG10201912943RA (en) 2015-10-02 2020-02-27 Symphogen As Anti-pd-1 antibodies and compositions
SI3443009T1 (en) 2016-04-12 2022-04-29 Symphogen A/S Anti-tim-3 antibodies and compositions
PL3458478T3 (en) 2016-05-18 2021-06-28 Boehringer Ingelheim International Gmbh Anti pd-1 and anti-lag3 antibodies for cancer treatment
SG11201900026TA (en) 2016-07-14 2019-01-30 Bristol Myers Squibb Co Antibodies against tim3 and uses thereof
JOP20190013A1 (en) 2016-08-25 2019-01-31 Lilly Co Eli Anti-tim-3 antibodies
WO2018069500A2 (en) 2016-10-13 2018-04-19 Symphogen A/S Anti-lag-3 antibodies and compositions
TWI780083B (en) 2016-11-18 2022-10-11 丹麥商賽門弗鎮公司 Anti-pd-1 antibodies and compositions
JOP20190133A1 (en) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
EA201992350A1 (en) * 2017-04-05 2020-03-23 Симфоген А/С COMBINED MEDICINES AIMED AT PD-1, TIM-3 AND LAG-3
JOP20190222A1 (en) 2017-04-11 2019-09-24 Zymeworks Inc Anti-pd-l1-anti-tim-3 bispecific antibodies

Also Published As

Publication number Publication date
US20200407444A1 (en) 2020-12-31
IL269644A (en) 2019-11-28
BR112019020662A2 (en) 2020-05-05
AU2022204078A1 (en) 2022-06-30
EP4116328A1 (en) 2023-01-11
PH12019502191A1 (en) 2020-06-15
RU2019134934A (en) 2021-05-05
CN110621698A (en) 2019-12-27
JP2020513009A (en) 2020-04-30
TW202235106A (en) 2022-09-16
TWI822101B (en) 2023-11-11
CN110621698B (en) 2024-04-12
CA3058960C (en) 2023-08-29
AU2018247916A1 (en) 2019-10-17
CA3058960A1 (en) 2018-10-11
CN114984209A (en) 2022-09-02
JP2022133296A (en) 2022-09-13
WO2018185232A1 (en) 2018-10-11
EA201992350A1 (en) 2020-03-23
US20220380470A1 (en) 2022-12-01
JP2024023222A (en) 2024-02-21
CL2019002850A1 (en) 2020-03-13
CO2019012080A2 (en) 2020-01-17
CA3185303A1 (en) 2018-10-11
US11939380B2 (en) 2024-03-26
TW201841652A (en) 2018-12-01
KR20190137105A (en) 2019-12-10
MA49042A (en) 2020-02-12
TWI801376B (en) 2023-05-11
RU2019134934A3 (en) 2022-01-14
MX2022007140A (en) 2022-07-19
SG11201908919XA (en) 2019-10-30
EP4230654A1 (en) 2023-08-23
SG10201912941PA (en) 2020-02-27
PE20191741A1 (en) 2019-12-12
KR20220083863A (en) 2022-06-20
MX2019011961A (en) 2019-12-05
EP3606957A1 (en) 2020-02-12

Similar Documents

Publication Publication Date Title
CL2021003196A1 (en) Combination therapies targeting pd-1, tim-3, and lag-3 (divisional application no. 201902850)
CL2018001685A1 (en) Heterocyclic compounds as immuno modulators.
CL2019000979A1 (en) Compositions and anti-lag-3 antibodies.
CO2020013762A2 (en) Compounds targeting brm and associated methods of use
CY1123397T1 (en) COMPOSITIONS INCLUDING A COMBINATION OF IPILIMUMAMP AND NIVOLUMAMP
CO2018003500A2 (en) Anti-pd-1 antibodies and compositions
CO2019012151A2 (en) Stable formulations of antibodies against programmed death receptor 1 (pd-1) and methods for their use
CL2018003582A1 (en) Compositions to modulate the expression of c9orf72 (divisional application 201702567)
MX2019012676A (en) 2-amino-quinoline derivatives.
ECSP18005520A (en) FACTOR XI ANTIBODIES AND METHODS OF USE
EA201992757A1 (en) SPECIFIC POINT INHIBITORS
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
MX2020001513A (en) Clec9a binding agents and use thereof.
BR112016029041A8 (en) use of a glutaminase inhibitor, pharmaceutical composition and pharmaceutical kit
WO2018115097A9 (en) Ophthalmic composition for treatment of dry eye disease
BR112016022318A2 (en) method, pharmaceutical composition for use in the treatment of retinal diseases and use of an antibody
PH12019501323A1 (en) Compositions comprising sulfated polysaccharides
TR201901077T4 (en) Combined Preparations for Cancer or Infection Treatment
BR112019017403A2 (en) compositions and methods for the treatment of cancer
PH12019502692A1 (en) Anti-cancer combination therapy
PL410665A1 (en) Arginase inhibitors and their therapeutical applications
UY34116A (en) THE NEUTRALIZING ANTIBODY OF THE MAT3 PROLACTIN RECEPTOR AND ITS THERAPEUTIC USE
MX2020003460A (en) Modulating the immune response using antibody-drug conjugates.
BR112015023074A2 (en) met-bonding agents and their use
UY37729A (en) NEW COMPOUNDS THAT INHIBIT THE ACTIVITY OF Nav1.7